ReviewDrug discovery today2008
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
Review in Drug discovery today, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 170 citations in OpenAlex.
- Review
- Oligo-Not Only for Silencing: Overlooked Potential for Multidirectional Action in Plants.International journal of molecular sciences · 2023Review
- A perspective on oligonucleotide therapy: Approaches to patient customization.Frontiers in pharmacology · 2022Review
- Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology.Oncotarget · 2021Article
- DNA with zwitterionic and negatively charged phosphate modifications: Formation of DNA triplexes, duplexes and cell uptake studies.Beilstein journal of organic chemistry · 2021Article
- Terminal Mono- and Bis-Conjugates of Oligonucleotides withInternational journal of molecular sciences · 2020Article
- Self-Assembled DNA-PEG Bottlebrushes Enhance Antisense Activity and Pharmacokinetics of Oligonucleotides.ACS applied materials & interfaces · 2020Article
- Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.International journal of molecular sciences · 2020Review
- Safety Considerations for Humans and Other Vertebrates Regarding Agricultural Uses of Externally Applied RNA Molecules.Frontiers in plant science · 2020Review
- Site-specific intestinal DMT1 silencing to mitigate iron absorption using pH-sensitive multi-compartmental nanoparticulate oral delivery system.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- Therapeutic perspectives for structural and functional abnormalities of cilia.Cellular and molecular life sciences : CMLS · 2019Review
- Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.Scientific reports · 2019Article
- Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart.Journal of visualized experiments : JoVE · 2018Article
- The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.Oncotarget · 2018Review
- Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.Molecules (Basel, Switzerland) · 2017Review
- Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.Biochemistry · 2017Article
- HDL and microRNA therapeutics in cardiovascular disease.Pharmacology & therapeutics · 2016Review
- CrxRdy Cat: A Large Animal Model for CRX-Associated Leber Congenital Amaurosis.Investigative ophthalmology & visual science · 2016Article
- Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.Cancer treatment reviews · 2016Review
- Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease.Clinical and translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antisense oligonucleotides can regulate gene expression in living cells. As such, they regulate cell function and division, and can modulate cellular responses to internal and external stresses and stimuli. Although encouraging results from preclinical and clinical studies have been obtained and significant progress has been made in developing these agents as drugs, they are not yet recognized as effective therapeutics. Several major hurdles remain to be overcome, including problems with efficacy, off-target effects, delivery and side effects. The lessons learned from antisense drug development can help in the development of other oligonucleotide-based therapeutics such as CpG oligonucleotides, RNAi and miRNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.